Surveillance Imaging in Pediatric Oncology

  • Martijn V. Verhagen
  • Kieran McHugh
  • Stephan D. VossEmail author
Part of the Pediatric Oncology book series (PEDIATRICO)


Surveillance imaging has become an increasingly important topic in pediatric oncology. More children than ever before are now alive at 5 years from the time of diagnosis.

With the number of cancer survivors growing each year, we are faced with the unique new challenge of determining how best to monitor these patients for disease recurrence. There has been increasing discussion related to how frequently surveillance imaging should be performed, with which imaging modalities, and whether aggressive surveillance imaging recommendations are justifiable in terms of the risks associated with frequent imaging and whether early relapse detection results in improved clinical outcomes.

This chapter will focus on the growing body of literature related to the role surveillance imaging plays in the care of patients with a variety of common pediatric malignancies. Evidence-based recommendations, where available, will be presented along with considerations for the appropriate use of imaging as an essential element of a comprehensive end-of-therapy monitoring plan.


Surveillance imaging Radiation risk Early detection Improved outcome Lead-time bias Length-time bias 


  1. 1.
    Weiser DA, Kaste SC, Siegel MJ, Adamson PC. Imaging in childhood cancer: a Society for Pediatric Radiology and Children’s Oncology Group Joint Task Force report. Pediatr Blood Cancer. 2013;60(8):1253–60. Scholar
  2. 2.
    Greer MC, Voss SD, States LJ. Pediatric cancer predisposition imaging: focus on whole-body MRI. Clin Cancer Res. 2017;23(11):e6–e13. Scholar
  3. 3.
    Kaste SC. Oncological imaging: tumor surveillance in children. Pediatr Radiol. 2011;41(Suppl 2):505–8. Scholar
  4. 4.
    Voss SD. Surveillance imaging in pediatric Hodgkin Lymphoma. Curr Hematol Malig Rep. 2013;8(3):218–25. Scholar
  5. 5.
    Goske MJ, Applegate KE, Bulas D, Butler PF, Callahan MJ, Coley BD, Don S, Frush DP, Hernanz-Schulman M, Kaste SC, Morrison G, Sidhu M, Strauss KJ, Treves ST, Alliance for Radiation Safety in Pediatric I. Image gently: progress and challenges in CT education and advocacy. Pediatr Radiol. 2011;41(Suppl 2):461–6. Scholar
  6. 6.
    Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol. 2008;81(965):362–78. Scholar
  7. 7.
    Mathews JD, Forsythe AV, Brady Z, Butler MW, Goergen SK, Byrnes GB, Giles GG, Wallace AB, Anderson PR, Guiver TA, McGale P, Cain TM, Dowty JG, Bickerstaffe AC, Darby SC. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013;346:f2360. Scholar
  8. 8.
    Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP, Howe NL, Ronckers CM, Rajaraman P, Sir Craft AW, Parker L, Berrington de Gonzalez A. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012;380(9840):499–505. Scholar
  9. 9.
    Howell L, Mensah A, Brennan B, Makin G. Detection of recurrence in childhood solid tumors. Cancer. 2005;103(6):1274–9. Scholar
  10. 10.
    Gawande RS, Gonzalez G, Messing S, Khurana A, Daldrup-Link HE. Role of diffusion-weighted imaging in differentiating benign and malignant pediatric abdominal tumors. Pediatr Radiol. 2013;43(7):836–45. Scholar
  11. 11.
    Humphries PD, Sebire NJ, Siegel MJ, Olsen OE. Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology. 2007;245(3):848–54. Scholar
  12. 12.
    Dauer LT, St Germain J, Meyers PA. Let’s image gently: reducing excessive reliance on CT scans. Pediatr Blood Cancer. 2008;51(6):838.; author reply 839-840. Scholar
  13. 13.
    Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology, the essentials. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.Google Scholar
  14. 14.
    Mckenzie K, Powell H. Health screening. Learn Disab Pract. 2004;7(10):34–8.CrossRefGoogle Scholar
  15. 15.
    Roebuck DJ, Villablanca JG, Maher K, Nelson MD Jr. Surveillance imaging in children with medulloblastoma (posterior fossa PNET). Pediatr Radiol. 2000;30(7):447–50. Scholar
  16. 16.
    Evans I, Thornton H, Chalmers I, Glasziou P. Earlier is not necessarily better. In: Testing treatments. 2nd ed. London: Pinter & Martin; 2011.Google Scholar
  17. 17.
    Marcus PM, Prorok PC, Miller AB, DeVoto EJ, Kramer BS. Conceptualizing overdiagnosis in cancer screening. J Natl Cancer Inst. 2015;107(4)
  18. 18.
    Ahmed BA, Connolly BL, Shroff P, Chong AL, Gordon C, Grant R, Greenberg ML, Thomas KE. Cumulative effective doses from radiologic procedures for pediatric oncology patients. Pediatrics. 2010;126(4):e851–8. Scholar
  19. 19.
    Chong AL, Grant RM, Ahmed BA, Thomas KE, Connolly BL, Greenberg M. Imaging in pediatric patients: time to think again about surveillance. Pediatr Blood Cancer. 2010;55(3):407–13. Scholar
  20. 20.
    Robbins E. Radiation risks from imaging studies in children with cancer. Pediatr Blood Cancer. 2008;51(4):453–7. Scholar
  21. 21.
    Hendee WR, O’Connor MK. Radiation risks of medical imaging: separating fact from fantasy. Radiology. 2012;264(2):312–21. Scholar
  22. 22.
    Berrington de Gonzalez A, Salotti JA, McHugh K, Little MP, Harbron RW, Lee C, Ntowe E, Braganza MZ, Parker L, Rajaraman P, Stiller C, Stewart DR, Craft AW, Pearce MS. Relationship between paediatric CT scans and subsequent risk of leukaemia and brain tumours: assessment of the impact of underlying conditions. Br J Cancer. 2016;114(4):388–94. Scholar
  23. 23.
    Berrington de Gonzalez A, Journy N, Lee C, Morton LM, Harbron RW, Stewart DR, Parker L, Craft AW, McHugh K, Little MP, Pearce MS. No association between radiation dose from pediatric CT scans and risk of subsequent Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2017;26(5):804–6. Scholar
  24. 24.
    Andronikou S. Letting go of what we believe about radiation and the risk of cancer in children. Pediatr Radiol. 2017;47(1):113–5. Scholar
  25. 25.
    Ulsh BA. Checking the foundation: recent radiobiology and the linear no-threshold theory. Health Phys. 2010;99(6):747–58. Scholar
  26. 26.
    Guillerman RP. From ‘Image Gently’ to image intelligently: a personalized perspective on diagnostic radiation risk. Pediatr Radiol. 2014;44(Suppl 3):444–9. Scholar
  27. 27.
    Callahan MJ, MacDougall RD, Bixby SD, Voss SD, Robertson RL, Cravero JP. Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations. Pediatr Radiol. 2017;48:21. Scholar
  28. 28.
    Soares BP, Lequin MH, Huisman T. Safety of contrast material use in children. Magn Reson Imaging Clin N Am. 2017;25(4):779–85. Scholar
  29. 29.
    Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010;152(7):409–17., W131–408. Scholar
  30. 30.
    Minn AY, Pollock BH, Garzarella L, Dahl GV, Kun LE, Ducore JM, Shibata A, Kepner J, Fisher PG. Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. J Clin Oncol. 2001;19(21):4135–40. Scholar
  31. 31.
    Yalcin B, Buyukpamukcu M, Akalan N, Cila A, Kutluk MT, Akyuz C. Value of surveillance imaging in the management of medulloblastoma. Med Pediatr Oncol. 2002;38(2):91–7.CrossRefGoogle Scholar
  32. 32.
    Kovanlikaya A, Karabay N, Cakmakci H, Uysal K, Olgun N, Ergor G. Surveillance imaging and cost effectivity in pediatric brain tumors. Eur J Radiol. 2003;47(3):188–92.CrossRefGoogle Scholar
  33. 33.
    Voss SD, Chen L, Constine LS, Chauvenet A, Fitzgerald TJ, Kaste SC, Slovis T, Schwartz CL. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin’s lymphoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2635–40. Scholar
  34. 34.
    Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR. Follow-up of patients with Hodgkin’s disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003;89(3):482–6. Scholar
  35. 35.
    Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma. 2003;44(1):123–5. Scholar
  36. 36.
    Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin’s disease: role of routine follow-up studies. J Clin Oncol. 1997;15(3):1123–30. Scholar
  37. 37.
    Rathore N, Eissa HM, Margolin JF, Liu H, Wu MF, Horton T, Kamdar K, Dreyer Z, Steuber P, Rabin KR, Redell M, Allen CE, McClain KL, Guillerman RP, Bollard CM. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012;29(5):415–23. Scholar
  38. 38.
    Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356–62. Scholar
  39. 39.
    Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT, Late Effects Study G. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin’s disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21(23):4386–94. Scholar
  40. 40.
    Punwani S, Taylor SA, Bainbridge A, Prakash V, Bandula S, De Vita E, Olsen OE, Hain SF, Stevens N, Daw S, Shankar A, Bomanji JB, Humphries PD. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging. Radiology. 2010;255(1):182–90.CrossRefGoogle Scholar
  41. 41.
    Federico SM, Brady SL, Pappo A, Wu J, Mao S, McPherson VJ, Young A, Furman WL, Kaufman R, Kaste S. The role of chest computed tomography (CT) as a surveillance tool in children with high-risk neuroblastoma. Pediatr Blood Cancer. 2015;62(6):976–81. Scholar
  42. 42.
    Owens C, Li BK, Thomas KE, Irwin MS. Surveillance imaging and radiation exposure in the detection of relapsed neuroblastoma. Pediatr Blood Cancer. 2016;63(10):1786–93. Scholar
  43. 43.
    Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging. 2005;5:116–27. Scholar
  44. 44.
    Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048–57. Scholar
  45. 45.
    Simon T, Hero B, Hunneman DH, Berthold F. Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer. 2003;39(13):1899–903.CrossRefGoogle Scholar
  46. 46.
    Guimaraes MD, Noschang J, Teixeira SR, Santos MK, Lederman HM, Tostes V, Kundra V, Oliveira AD, Hochhegger B, Marchiori E. Whole-body MRI in pediatric patients with cancer. Cancer Imaging. 2017;17(1):6. Scholar
  47. 47.
    McHugh K, Roebuck DJ. Pediatric oncology surveillance imaging: two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow-up. Pediatr Blood Cancer. 2014;61(1):3–6. Scholar
  48. 48.
    Davidoff AM. Wilms tumor. Adv Pediatr. 2012;59(1):247–67. Scholar
  49. 49.
    Kembhavi SA, Qureshi S, Vora T, Chinnaswamy G, Laskar S, Ramadwar M, Arora B. Understanding the principles in management of Wilms’ tumour: can imaging assist in patient selection? Clin Radiol. 2013;68(7):646–53. Scholar
  50. 50.
    Green DM. Considerations in the diagnosis and management of pediatric patients with favorable histology wilms tumor who present with only pulmonary nodules. Pediatr Blood Cancer. 2016;63(4):589–92. Scholar
  51. 51.
    Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, Miser J, Ritchey ML, Thomas PR, Grundy PE, D’Angio GJ, Beckwith JB, Shamberger RC, Haase GM, Donaldson M, Weetman R, Coppes MJ, Shearer P, Coccia P, Kletzel M, Macklis R, Tomlinson G, Huff V, Newbury R, Weeks D, National Wilms Tumor Study G. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer. 2008;50(2):236–41. Scholar
  52. 52.
    Breslow N, Sharples K, Beckwith JB, Takashima J, Kelalis PP, Green DM, D’Angio GJ. Prognostic factors in nonmetastatic, favorable histology Wilms’ tumor. Results of the Third National Wilms’ Tumor Study. Cancer. 1991;68(11):2345–53.CrossRefGoogle Scholar
  53. 53.
    Wilimas JA, Hammond E, Douglass EC, Champion J, Parvey L, Coburn T. The value of computerized tomography as a routine follow-up procedure for patients with Wilms’ tumor. Med Pediatr Oncol. 1984;12(3):221–3.CrossRefGoogle Scholar
  54. 54.
    Kaste SC, Brady SL, Yee B, McPherson VJ, Kaufman RA, Billups CA, Daw NC, Pappo AS. Is routine pelvic surveillance imaging necessary in patients with Wilms tumor? Cancer. 2013;119(1):182–8. Scholar
  55. 55.
    Mirza W, McHugh K, Aslam M, Sajjad Z, Abid W, Youssef T, Ali A, Fadoo Z. CT pelvis in children; should we routinely scan pelvis for wilms tumor and hepatoblastoma? Implications for imaging protocol development. J Coll Physicians Surg Pak. 2015;25(10):768770–695. Scholar
  56. 56.
    Dumba M, Jawad N, McHugh K. Neuroblastoma and nephroblastoma: a radiological review. Cancer Imaging. 2015;15:5. Scholar
  57. 57.
    Mullen EA, Chi YY, Hibbitts E, Anderson JR, Steacy KJ, Geller JI, Green DM, Khanna G, Malogolowkin MH, Grundy PE, Fernandez CV, Dome JS. Impact of surveillance imaging modality on survival after recurrence in patients with favorable-histology wilms tumor: a report from the Children’s Oncology Group. J Clin Oncol. 2018;18:JCO1800076.
  58. 58.
    Semeraro M, Branchereau S, Maibach R, Zsiros J, Casanova M, Brock P, Domerg C, Aronson DC, Zimmermann A, Laithier V, Childs M, Roebuck D, Perilongo G, Czauderna P, Brugieres L. Relapses in hepatoblastoma patients: clinical characteristics and outcome--experience of the International Childhood Liver Tumour Strategy Group (SIOPEL). Eur J Cancer. 2013;49(4):915–22. Scholar
  59. 59.
    Rojas Y, Guillerman RP, Zhang W, Vasudevan SA, Nuchtern JG, Thompson PA. Relapse surveillance in AFP-positive hepatoblastoma: re-evaluating the role of imaging. Pediatr Radiol. 2014;44(10):1275–80. Scholar
  60. 60.
    Kan JH, Hwang M, Lowas SR, Hernanz-Schulman M. Impact of pelvic CT on staging, surveillance, and survival of pediatric patients with Wilms tumor and hepatoblastoma. AJR Am J Roentgenol. 2011;196(5):W515–8. Scholar
  61. 61.
    Shelmerdine SC, Roebuck DJ, Towbin AJ, McHugh K. MRI of paediatric liver tumours: how we review and report. Cancer Imaging. 2016;16(1):21.
  62. 62.
    Puri A, Gulia A, Hawaldar R, Ranganathan P, Badwe RA. Does intensity of surveillance affect survival after surgery for sarcomas? Results of a randomized noninferiority trial. Clin Orthop Relat Res. 2014;472(5):1568–75. Scholar
  63. 63.
    Rothermundt C, Whelan JS, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Seddon BM. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer. 2014;110(10):2420–6.
  64. 64.
    Postovsky S, Barzilai M, Meller I, Kollander Y, Futerman B, Ben Arush MW. Does regular follow-up influence the survival of patients with sarcoma after recurrence? The Miri Shitrit pediatric oncology department experience. J Pediatr Hematol Oncol. 2008;30(3):189–95. Scholar
  65. 65.
    Korholz D, Verheyen J, Kemperdick HF, Gobel U. Evaluation of follow-up investigations in osteosarcoma patients: suggestions for an effective follow-up program. Med Pediatr Oncol. 1998;30(1):52–8.CrossRefGoogle Scholar
  66. 66.
    Meyer JS, Nadel HR, Marina N, Womer RB, Brown KL, Eary JF, Gorlick R, Grier HE, Randall RL, Lawlor ER, Lessnick SL, Schomberg PJ, Kailo MD. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2008;51(2):163–70. Scholar
  67. 67.
    Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol. 2012;34(2):131–6. Scholar
  68. 68.
    Lin JL, Guillerman RP, Russell HV, Lupo PJ, Nicholls L, Okcu MF. Does routine imaging of patients for progression or relapse improve survival in rhabdomyosarcoma? Pediatr Blood Cancer. 2016;63(2):202–5. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Martijn V. Verhagen
    • 1
  • Kieran McHugh
    • 1
  • Stephan D. Voss
    • 2
    Email author
  1. 1.Great Ormond Street Hospital for ChildrenLondonUK
  2. 2.Boston Children’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations